Hirofumi Chiba

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 8

Top Topics

Emergency Department

Glycemic Control

Fine Needle Aspiration

Small Cell Lung Cancer

Top Venues

Journal of cancer research and clinical oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Naoki Shijubou, Toshiyuki Sumi, Terufumi Kubo, Kenta Sasaki, Tomohide Tsukahara, Takayuki Kanaseki, Kenji Murata, Yoshiko Keira, Kotomi Terai, Tatsuru Ikeda, Yuichi Yamada, Hirofumi Chiba, Yoshihiko Hirohashi, Toshihiko Torigoe
Prognostic significance of immunohistochemical classification utilizing biopsy specimens in patients with extensive-disease small-cell lung cancer treated with first-line chemotherapy and immune checkpoint inhibitors. Journal of cancer research and clinical oncology 150 (3) (2024)
Naoki Shijubou, Toshiyuki Sumi, Terufumi Kubo, Kenta Sasaki, Tomohide Tsukahara, Takayuki Kanaseki, Kenji Murata, Yoshiko Keira, Kotomi Terai, Tatsuru Ikeda, Yuichi Yamada, Hirofumi Chiba, Yoshihiko Hirohashi, Toshihiko Torigoe
Prognostic significance of immunohistochemical classification utilizing biopsy specimens in patients with extensive-disease small-cell lung cancer treated with first-line chemotherapy and immune checkpoint inhibitors. Journal of cancer research and clinical oncology 150 (3) (2024)
Naoki Shijubou, Toshiyuki Sumi, Terufumi Kubo, Kenta Sasaki, Tomohide Tsukahara, Takayuki Kanaseki, Kenji Murata, Yoshiko Keira, Kotomi Terai, Tatsuru Ikeda, Yuichi Yamada, Hirofumi Chiba, Yoshihiko Hirohashi, Toshihiko Torigoe
Prognostic significance of immunohistochemical classification utilizing biopsy specimens in patients with extensive-disease small-cell lung cancer treated with first-line chemotherapy and immune checkpoint inhibitors. Journal of cancer research and clinical oncology 150 (3) (2024)
Naoki Shijubou, Toshiyuki Sumi, Terufumi Kubo, Kenta Sasaki, Tomohide Tsukahara, Takayuki Kanaseki, Kenji Murata, Yoshiko Keira, Kotomi Terai, Tatsuru Ikeda, Yuichi Yamada, Hirofumi Chiba, Yoshihiko Hirohashi, Toshihiko Torigoe
Prognostic significance of immunohistochemical classification utilizing biopsy specimens in patients with extensive-disease small-cell lung cancer treated with first-line chemotherapy and immune checkpoint inhibitors. Journal of cancer research and clinical oncology 150 (3) (2024)
Naoki Shijubou, Toshiyuki Sumi, Terufumi Kubo, Kenta Sasaki, Tomohide Tsukahara, Takayuki Kanaseki, Kenji Murata, Yoshiko Keira, Kotomi Terai, Tatsuru Ikeda, Yuichi Yamada, Hirofumi Chiba, Yoshihiko Hirohashi, Toshihiko Torigoe
Prognostic significance of immunohistochemical classification utilizing biopsy specimens in patients with extensive-disease small-cell lung cancer treated with first-line chemotherapy and immune checkpoint inhibitors. Journal of cancer research and clinical oncology 150 (3) (2024)
Naoki Shijubou, Toshiyuki Sumi, Terufumi Kubo, Kenta Sasaki, Tomohide Tsukahara, Takayuki Kanaseki, Kenji Murata, Yoshiko Keira, Kotomi Terai, Tatsuru Ikeda, Yuichi Yamada, Hirofumi Chiba, Yoshihiko Hirohashi, Toshihiko Torigoe
Prognostic significance of immunohistochemical classification utilizing biopsy specimens in patients with extensive-disease small-cell lung cancer treated with first-line chemotherapy and immune checkpoint inhibitors. Journal of cancer research and clinical oncology 150 (3) (2024)
Naoki Shijubou, Toshiyuki Sumi, Terufumi Kubo, Kenta Sasaki, Tomohide Tsukahara, Takayuki Kanaseki, Kenji Murata, Yoshiko Keira, Kotomi Terai, Tatsuru Ikeda, Yuichi Yamada, Hirofumi Chiba, Yoshihiko Hirohashi, Toshihiko Torigoe
Prognostic significance of immunohistochemical classification utilizing biopsy specimens in patients with extensive-disease small-cell lung cancer treated with first-line chemotherapy and immune checkpoint inhibitors. Journal of cancer research and clinical oncology 150 (3) (2024)
Naoki Shijubou, Toshiyuki Sumi, Yuichi Yamada, Hisashi Nakata, Yuji Mori, Hirofumi Chiba
Immunological and nutritional predictive factors in patients receiving pembrolizumab for the first-line treatment of non-small cell lung cancer. Journal of cancer research and clinical oncology 148 (8) (2022)